Results 31 to 40 of about 51,155 (263)

Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes

Clinical and Experimental Gastroenterology, 2023
Malcolm Irani,1 Christopher Fan,1 Kerri Glassner,1– 3 Bincy P Abraham1– 3 1Houston Methodist Gastroenterology Associates, Houston Methodist Hospital, Houston, TX, USA; 2Weill Cornell Medical College, New York, NY, USA; 3Houston Methodist Academic ...
Irani M, Fan C, Glassner K, Abraham BP
doaj  

Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis

Acta Dermato-Venereologica, 2023
The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score.
Farnam Barati Sedeh, Thorunn Elísabet Michaelsdóttir, Mattias Arvid Simon Henning, Gregor Borut Ernst Jemec, Kristina Sophie Ibler   +4 more
doaj   +1 more source

Lilrb4a Suppression Reprograms Microglia to Mitigate APOE4‐Associated Amyloid Plaques and Cerebral Amyloid Angiopathy in Association With a PPAR‐Linked Pro‐Clearance State

Advanced Science, EarlyView.
Targeting Lilrb4a in Apolipoprotein E4 (APOE4)‐associated Alzheimer's disease (AD) reprograms microglia toward a beneficial, phagocytic state. Genetic deletion or antisense inhibition of Lilrb4a suppresses p‐SHP2/NF‐κB/STAT1 signaling, restores PPAR‐linked lipid and energy metabolism, and reduces amyloid plaque burden and cerebral amyloid angiopathy ...
Changxu Nie, Ruixi Yang, Xiaotong Wang, Ping Jia, Xueqi Zhang, Yaqi Dai, Xue Bai, Sijia Duan, Yufeng Li, Peng Zheng, Xin Tian, Li Jiang, Chao Wang   +12 more
wiley   +1 more source

Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: A case report

SAGE Open Medical Case Reports
Vitiligo is a common, autoimmune, depigmenting disorder of the skin. Janus Kinase inhibitors have emerged as promising topical and oral therapeutic options for vitiligo.
Seyyon Satkunanathan, Mina Boshra, Janis Chang, Reetesh Bose   +3 more
doaj   +1 more source

Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report

SAGE Open Medical Case Reports, 2022
This case report describes the first successful treatment of alopecia areata and atopic dermatitis with the Janus kinase 1 inhibitor upadacitinib in a paediatric patient.
Adrienn N Bourkas, Cathryn Sibbald
doaj   +1 more source

RNA‐Binding Protein RBM25 Targets the mRNA Stability of GTPase Rab22a to Restrict Viral Entry and Infection

Advanced Science, EarlyView.
This study identifies RNA‐binding protein RBM25 as a broad‐spectrum antiviral factor acting independently of type I interferon. It blocks viral entry by suppressing GTPase Rab22a via the RC3H1‐mediated destabilization of Rab22a mRNA. Viral downregulation of RBM25 enhances GTPase Rab22a expression and viral entry, revealing an unreported post ...
Yingying Ding, Huiying Chen, Yuyu Jiang, Chunyan Zhao, Jie Bai, Yan Xiang, Zeting Wang, Xixi Wang, Bing Rui, Wanda Tang, Yue Ding, Zhenzhen Zhan, Yunkai Zhang, Xingguang Liu   +13 more
wiley   +1 more source

Indirect inhibition of the NLRP3-interleukin-1β axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitis

Nature Communications
Tofacitinib, a pan–Janus kinase inhibitor, and the Janus kinase 1–preferential inhibitors Upadacitinib and Filgotinib are approved for the treatment of ulcerative colitis, yet their molecular mechanisms of action remain incompletely understood.
Beibei Liu, Marianne R. Spalinger, Annalisa Invernizzi, Eike Gerdes, Babett Steglich, Marlene Schwarzfischer, Andres Machicote, Penelope Pelczar, Doris Pöhlmann, Mikolaj Nawrocki, Marius Böttcher, Ayob Aleko, Lis Noelia Velasquez, Sandra Wende, Franziska Stallbaum, Justus Neuendorff, Saskia Grosshauser, Franziska Muscate, Gemma Douilhet, Laura Garcia Perez, Morsal Sabihi, Katharina Möller, Florian Viehweger, Jan P. Sutter, Christoph Kilian, Yogesh Kumar, Thorben Fründt, Guido Sauter, Thomas Rösch, Nicola Gagliani, Amedeo Caflisch, Michael Scharl, Samuel Huber   +32 more
doaj   +1 more source

A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics

Frontiers in Medicine
IntroductionAlopecia areata (AA) is an autoimmune, inflammatory condition characterized by non-scarring hair loss on the scalp, face, or body. It can significantly affect a person’s quality of life (QoL) and mental health.MethodsUsing a modified Delphi ...
Charles W. Lynde, Lyn Guenther, Anneke Andriessen, Sameh Hanna, Elena Netchiporouk, Vimal Prajapati, Vimal Prajapati, Marni Wiseman, Marni Wiseman, Julien Ringuet, Julien Ringuet   +10 more
doaj   +1 more source

c-Src binds to the cancer drug Ruxolitinib with an active conformation. [PDF]

PLoS ONE, 2014
The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase.
Yankun Duan, Lin Chen, Yongheng Chen, Xue-gong Fan   +3 more
doaj   +1 more source

ROS‐Targeted Nanomotor Therapy in OA: Cartilage Protection and Pain Relief

Advanced Science, EarlyView.
ROS‐responsive NM@MET nanomotors utilize elevated ROS in osteoarthritic joints to promote deep penetration into cartilage and synovium and enable sustained metformin release. By scavenging ROS, regulating NRF2/KEAP1 signaling, protecting chondrocytes, suppressing synovial inflammation, and attenuating nociceptive signaling, NM@MET alleviates pain and ...
Meng Zheng, Changyu Liu, Qin Xia, Arndt F. Schilling, Jiawei Jiang, Renpeng Peng, Zixing Shu, Tian Ma, Danni Luo, Yaoyu Zhang, Yibo Fan, Xuyuan Zhang, Song Li, Kai Wang, Wentao Ke, Yuan Xiong, Yuanli Zhu, Fangzhi Mou, Jun Xiao, Hao Zhu   +19 more
wiley   +1 more source